MIGHTY MEDIC Org.’s Advanced Clinical Major Seminary and Educational Forum on Clinical Lipidology, Metabolic Disorders, Extracorporeal Therapeutic Techniques, and Atherosclerosis Prevention Seminario Clinico Avanzato e formazione continua in Lipidologia Clinica, Disturbi del Metabolismo, Tecniche Terapeutiche Extracorporee e Prevenzione dell’Aterosclerosi Peschiera del Garda, Italy, April 18-19, 2024 LETZTES PROGRAMM


PICTURES OF THE EVENT October 7-8, 2021 – Verona 16th LIPID CLUB AND THERAPEUTIC APHERESIS Seminary and Educational Forum on Clinical Lipidology, Metabolic Disorders, Extracorporeal Therapeutic Techniques and Atherosclerosis Prevention Verona, October 7-8, 2021Camera di Commercio, Industria Artigianato e Agricoltura di Verona Corso Porta Nuova, 96 – 37122 Verona VR …

Continue reading

FCS Announcement

We are collecting anonymised information on patients with familial chylomicronaemia syndrome (FCS)/multifactorial chylomicronaemia syndrome (MCS) as a service evaluation & quality improvement project. The project aims to improve understanding of natural history of FCS and to validate the use of FCS scoring algorithm. The project is approved by Manchester University …

Continue reading

E-ISFA 2020 Announcement

3rd Congress of the European Group – International Society for Apheresis (E-ISFA) Dresden, March 19 to 21, 2020   Congress Topics Recent progress in lipoprotein apheresis Homozygous familial hypercholesterolemia Lipoprotein(a) Competition with drugs Plasma exchange Immunoadsorption – indications, results, future perspectives Experience with extracorporeal therapy in children and during pregnancy Apheresis …

Continue reading

The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia – a post-hoc analysis of a Phase 3, single-arm, open-label trial.

OBJECTIVE: Lomitapide (a microsomal triglyceride transfer protein inhibitor) is an adjunctive treatment for homozygous familial hypercholesterolaemia (HoFH), a rare genetic condition characterised by elevated low-density lipoprotein-cholesterol (LDL-C), and premature, severe, accelerated atherosclerosis. Standard of care for HoFH includes lipid-lowering drugs and lipoprotein apheresis. We conducted a post-hoc analysis using data …

Continue reading